Table 2.

Baseline characteristics of glomerular neuropathy patients: diagnosis, treatment, and disease duration

	Admission Status				P Value
	Outpatients		Hospitalized
SLE GN or vasculitis (systemic GN)	26	42%	26	41%	>0.99
Lupus nephritis	19	31%	11	18%	0.1
Vasculitis	7	11%	15	24%	0.1
IgA nephropathy	13	21%	5	8%	0.04
FSGS or MCD	11	18%	9	14%	0.63
Membranous nephropathy	8	13%	5	8%	0.4
Amyloidosis/fibrillary GN	2	3%	2	3%	>0.99
Thrombotic microangiopathy	1	2%	0	0%	0.5
Membranoproliferative GN	0	0%	4	6%	0.12
Post-infectious GN	0	0%	2	3%	0.5
Not specified	1	2%	10	16%	0.009
Immunosuppression at time of COVID-19	38	61%	35	56%	0.59
Prednisone	23	37%	23	37%	>0.99
Prednisone dose, mg/d		8.6 (7.4)		15.7 (22.0)	0.21
MMF	15	24%	11	18%	0.39
AZA	1	2%	4	6%	0.37
RTX	1	2%	11	18%	0.004
CNI	2	3%	15	24%	0.001
Therapy reduction/withdrawal during COVID-19a
Prednisone	0	0%	1	4%	>0.99
MMF	3	20%	8	73%	0.007
AZA	0	0%	3	75%	0.24
CNI	1	50%	1	7%	0.47
Duration of GN disease
1–6 mo	5	8%	13	27%	0.004
6–12 mo	0	0%	6	12%
12–24 mo	9	15%	5	10%
2–5 yr	17	28%	6	12%
>5 yr	29	48%	19	39%
Active GN disease at COVID-19 onset	5	8%	8	18%	0.23

Continuous data are reported as number of non-missing variables, mean (SD); categorical data are reported as number of nonmissing variables and percentages. Active GN disease was defined based on reporter assessment of patient’s clinical and laboratory features. P values refer to Fisher’s exact and to Cochran–Armitage test for trend (with exact P values) for GN disease. GN, history of glomerular disease; MCD, minimal change disease; SLE, systemic lupus erythematosus; MMF, mycophenolate mofetil; AZA, azathioprine; CNI, calcineurin inhibitor; RTX, rituximab.

^aOut of patients on immunosuppression at time of COVID-19.